- Home
- BSET vs SKYE Comparison
BSET vs SKYE Comparison
Compare BSET & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BSET
- SKYE
- Stock Information
- Founded
- BSET 1902
- SKYE 2012
- Country
- BSET United States
- SKYE United States
- Employees
- BSET N/A
- SKYE N/A
- Industry
- BSET Home Furnishings
- SKYE Biotechnology: Pharmaceutical Preparations
- Sector
- BSET Consumer Discretionary
- SKYE Health Care
- Exchange
- BSET Nasdaq
- SKYE Nasdaq
- Market Cap
- BSET 135.3M
- SKYE 115.9M
- IPO Year
- BSET 1987
- SKYE N/A
- Fundamental
- Price
- BSET $16.22
- SKYE $3.89
- Analyst Decision
- BSET
- SKYE Buy
- Analyst Count
- BSET 0
- SKYE 6
- Target Price
- BSET N/A
- SKYE $16.60
- AVG Volume (30 Days)
- BSET 52.9K
- SKYE 392.1K
- Earning Date
- BSET 07-09-2025
- SKYE 08-07-2025
- Dividend Yield
- BSET 4.91%
- SKYE N/A
- EPS Growth
- BSET N/A
- SKYE N/A
- EPS
- BSET 0.28
- SKYE N/A
- Revenue
- BSET $326,469,000.00
- SKYE N/A
- Revenue This Year
- BSET $3.39
- SKYE N/A
- Revenue Next Year
- BSET $3.63
- SKYE N/A
- P/E Ratio
- BSET $58.01
- SKYE N/A
- Revenue Growth
- BSET N/A
- SKYE N/A
- 52 Week Low
- BSET $12.11
- SKYE $1.14
- 52 Week High
- BSET $19.75
- SKYE $7.47
- Technical
- Relative Strength Index (RSI)
- BSET 40.39
- SKYE 55.34
- Support Level
- BSET $15.36
- SKYE $3.25
- Resistance Level
- BSET $16.02
- SKYE $3.84
- Average True Range (ATR)
- BSET 0.73
- SKYE 0.34
- MACD
- BSET -0.32
- SKYE -0.06
- Stochastic Oscillator
- BSET 12.90
- SKYE 55.65
About BSET Bassett Furniture Industries Incorporated
Bassett Furniture Industries Inc is a manufacturer, marketer, and retailer of home furnishings products in the United States. It operates through the following segments: The Wholesale segment focuses on the design, manufacture, sourcing, sale, and distribution of furniture products, the Retail segment which consists of company-owned stores, and the Corporate and others segment. Majority of revenue is from Wholesale sales of furniture and accessories.
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.